Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
Crohn’s Disease Treatment Market Size Expansion: A Snapshot of Growth Between 2024 and 2029
In recent times, the market size for treating Crohn’s disease has seen substantial growth. A rise from $12.45 billion in 2024 to $13.1 billion in 2025 is expected, representing a compound annual growth rate (CAGR) of 5.2%. Factors that have contributed to the growth in the historical period include an increase in the prevalence of the disease, the evolution of diagnostic options, the use of biological therapies, heightened patient education and awareness, along with advancements in clinical research and development.
The market for treating Crohn’s disease is set to experience robust expansion in the coming years, with it forecasted to reach $17.34 billion by 2029, showcasing a compound annual growth rate (CAGR) of 7.3%. This projected growth can be credited to several factors such as the advent of personalized medicine tactics, broader biologics market development, evolving treatment protocols, greater expenditure on healthcare, and cooperative research endeavors. Future market trends will encompass telemedicine for patient supervision, exploration of immune modulation strategies, the embracing of patient-centric care frameworks, and the integration of digital health solutions.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
Key Drivers Behind the Expansion of the Crohn’s Disease Treatment Market: Insights and Trends
The anticipated rise in cases of inflammatory bowel disorders is predicted to drive the expansion of the Crohn’s disease treatment market. These disorders are chronic conditions leading to inflammation of the gastrointestinal tract, potentially causing harm to any part of the digestive system ranging from the mouth to the rectum. Treatment for Crohn’s disease works by reducing intestinal inflammation, managing symptom outbreaks, and maintaining remission. In fact, the National Center for Biotechnology Information, a US-based government organization, reported in September 2023 that rates of both Crohn’s disease and ulcerative colitis were on the rise.
They projected an incidence of inflammatory bowel disease at 825 cases per 100,000 people in 2023, with 410 cases attributed to Crohn’s disease and the remaining 414 to ulcerative colitis and IBD-u. Consequently, the escalating incidence of these disorders is spurring the growth of the Crohn’s disease treatment market.
Which Segments in the Crohn’s Disease Treatment Industry Are Seeing the Fastest Growth?
The crohn’s disease treatment market covered in this report is segmented –
1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other Applications
Subsegments:
1) By Antibiotics: Metronidazole, Ciprofloxacin, Other Antibiotics
2) By Amino Salicylates: Mesalamine, Sulfasalazine, Other Amino Salicylates
3) By Corticosteroids: Prednisone, Budesonide, Other Corticosteroids
4) By Immunomodulators: Azathioprine, Methotrexate, Mercaptopurine
5) By Other Drug Types: Biologics, Small Molecules, Other Treatments
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
Which New Trends Will Create Growth Opportunities in the Crohn’s Disease Treatment Market?
Key businesses in the field of crohn’s disease treatment are introducing new medications such as the biosimilar ustekinumab and securing their approval, with the aim of offering more efficient and readily available treatment choices for patients, thus enhancing patient prognosis and life quality. The term biosimilar ustekinumab refers to a biologic medication that closely resembles the original ustekinumab (a monoclonal antibody) used to treat autoimmune disorders. For instance, Sandoz International GmbH, a pharmaceutical corporation based in Switzerland, unveiled Pyzchiva (ustekinumab) throughout Europe in July 2024. This marked the first available ustekinumab biosimilar in all strengths, including a 130 mg vial especially for Crohn’s disease. The product is intended for use by adults and children over the age of six with plaque psoriasis, psoriatic arthritis, and Crohn’s disease, thereby augmenting Sandoz’s immunology product range and striving to improve accessibility to cost-effective treatments for chronic inflammatory disease.
Which Global Regions Are Powering Demand in the Crohn’s Disease Treatment Market?
North America was the largest region in the global Crohn’s disease treatment market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the Crohn’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
How Key Players Are Driving Growth in the Crohn’s Disease Treatment Market?
Major companies operating in the crohn’s disease treatment market include AbbVie Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Bristol-Myers Squibb Company, Galapagos NV, Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Mylan N.V., Glenmark Pharmaceuticals, Tillotts Pharma AG, Dr. Falk Pharma GmbH, Shire Pharmaceuticals, Salix Pharmaceuticals, Prometheus Laboratories Inc., Arena Pharmaceuticals Inc.
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…x?id=10852
How Our Market Research Reports Help Maximize ROI Across Industries:
* Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
* Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
* Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
